CARLSMED, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
CARL$14.71-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(in thousands, except for share amounts)
| Series A ConvertiblePreferred Stock · Series B ConvertiblePreferred Stock · Series C ConvertiblePreferred Stock · Common Stock · Additional · Accumulated Other · Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Paid-InCapital | AccumulatedDeficit | Comprehensive Loss | Stockholders’Equity (Deficit) | |
| Balance as of December 31, 2025 | — | $— | — | $— | — | $— | 26,604,505 | $— | $199,674 | $(100,805) | $— | $98,869 |
| Vesting of early exercised stock options | — | — | — | — | — | — | 8,961 | — | 10 | — | — | 10 |
| Cashless exercise of warrants | — | — | — | — | — | — | 30,366 | — | — | — | — | — |
| Exercise of vested stock options | — | — | — | — | — | — | 537,669 | — | 436 | — | — | 436 |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 1,629 | — | — | 1,629 |
| Net loss | — | — | — | — | — | — | — | — | — | (8,696) | — | (8,696) |
| Balance as of March 31, 2026 | — | $— | — | $— | — | $— | 27,181,501 | $— | $201,749 | $(109,501) | $— | $92,248 |
| Vesting of early exercised stock options | — | — | — | — | — | — | 8,961 | — | 11 | — | — | 11 |
| Exercise of vested stock options | — | — | — | — | — | — | 10,019 | — | 36 | — | — | 36 |
| Issuance of common stock in connection with the employee stock purchase plan | — | — | — | — | — | — | 25,278 | — | 207 | — | — | 207 |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 2,271 | — | — | 2,271 |
| Other comprehensive loss | — | — | — | — | — | — | — | — | — | — | (17) | (17) |
| Net loss | — | — | — | — | — | — | — | — | — | (10,510) | — | (10,510) |
| Balance as of June 30, 2026 | — | $— | — | $— | — | $— | 27,225,759 | $— | $204,274 | $(120,011) | $(17) | $84,246 |
| Vesting of early exercised stock options | — | — | — | — | — | — | 41,816 | — | 49 | — | — | 49 |
| Exercise of vested stock options | — | — | — | — | — | — | 96,963 | — | 367 | — | — | 367 |
| Issuance of common stock for vested RSUs | — | — | — | — | — | — | 23,108 | — | — | — | — | — |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 3,278 | — | — | 3,278 |
| Other comprehensive loss | — | — | — | — | — | — | — | — | — | — | (21) | (21) |
| Net loss | — | — | — | — | — | — | — | — | — | (12,245) | — | (12,245) |
| Balance as of September 30, 2026 | — | $— | — | $— | — | $— | 27,387,646 | $— | $207,968 | $(132,256) | $(38) | $75,674 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.